Product Description
Mechanisms of Action: Osteoclast Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gador
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Chronic Pain|Low Back Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2015-004269-96 | P2 |
Active, not recruiting |
Chronic Pain|Low Back Pain |
2017-08-24 |